The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous systemincluding psychiatric drugsare assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine’s (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA’s new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.
Compre este e-book e ganhe mais 1 GRÁTIS!
Língua Inglês ● Formato EPUB ● Páginas 88 ● ISBN 9780309186483 ● Editor Bruce Altevogt & Miriam Davis ● Editora National Academies Press ● Publicado 2010 ● Carregável 3 vezes ● Moeda EUR ● ID 7149718 ● Proteção contra cópia Adobe DRM
Requer um leitor de ebook capaz de DRM